Why read this article?
Aimee Raleigh's blog post on LifeSciVC provides an insightful framework for how VCs evaluate new biotech products and pipelines during the diligence process. It outlines the critical steps and considerations that VCs prioritise, offering a clear guide to presenting your data effectively. Understanding these VC evaluation criteria can help you present your product data in a compelling, yet truthful manner, enhancing the chances of securing investment.
A few key takeaways
This post details how VCs evaluate biotech products and pipeline, emphasizing the importance of a few topics including:
- Target Product Profile (TPP): Establishing a clear and detailed TPP early in the diligence process is crucial. This involves defining the therapeutic benefits and differentiation potential of the product, which helps in assessing the viability and market fit.
- Competitive Analysis: Early benchmarking against existing and potential competitors is vital. Understanding the competitive landscape can highlight unique selling points and areas that need improvement.
- Validation and Risk Assessment: The diligence process should include robust target validation and a clear path to demonstrating proof of concept.
- Stakeholder Engagement: Engage key opinion leaders, patients, and investors early in the process to pressure-test the product thesis. Their feedback can provide valuable insights and drive enthusiasm for the project.
Deconstructing The Diligence Process: An Approach to Vetting New Product Theses
Original Source: Deconstructing the Diligence Process: An Approach to Vetting New Product Theses (LifeSciVC)
Diligence Deep Dives